(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 9.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Moderna's revenue in 2026 is $2,225,000,000.On average, 26 Wall Street analysts forecast MRNA's revenue for 2026 to be $845,948,304,188, with the lowest MRNA revenue forecast at $753,497,105,841, and the highest MRNA revenue forecast at $926,099,128,506. On average, 25 Wall Street analysts forecast MRNA's revenue for 2027 to be $977,681,342,176, with the lowest MRNA revenue forecast at $753,100,319,582, and the highest MRNA revenue forecast at $1,424,462,669,810.
In 2028, MRNA is forecast to generate $1,165,758,028,942 in revenue, with the lowest revenue forecast at $852,296,884,332 and the highest revenue forecast at $1,350,263,639,377.